Hanson L - Search Results

1

Tzabazis A, Kori S, Mechanic J, Miller J, Pascual C, Manering N, Carson D, Klukinov M, Spierings E, Jacobs D, Cuellar J, Frey WH 2nd, Hanson L, Angst M, Yeomans DC. Tzabazis A, et al. Among authors: hanson l. Headache. 2017 May;57 Suppl 2:64-75. doi: 10.1111/head.13082. Headache. 2017. PMID: 28485846 Review.

2

Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis.

Ross TM, Martinez PM, Renner JC, Thorne RG, Hanson LR, Frey WH 2nd. Ross TM, et al. Among authors: hanson lr. J Neuroimmunol. 2004 Jun;151(1-2):66-77. doi: 10.1016/j.jneuroim.2004.02.011. J Neuroimmunol. 2004. PMID: 15145605

3

The window of opportunity for treatment of focal cerebral ischemic damage with noninvasive intranasal insulin-like growth factor-I in rats.

Liu XF, Fawcett JR, Hanson LR, Frey WH 2nd. Liu XF, et al. J Stroke Cerebrovasc Dis. 2004 Jan-Feb;13(1):16-23. doi: 10.1016/j.jstrokecerebrovasdis.2004.01.005. J Stroke Cerebrovasc Dis. 2004. PMID: 17903945

4

Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS.

Hanson LR, Frey WH 2nd. Hanson LR, et al. J Neuroimmune Pharmacol. 2007 Mar;2(1):81-6. doi: 10.1007/s11481-006-9039-x. Epub 2006 Sep 15. J Neuroimmune Pharmacol. 2007. PMID: 18040829 Review.

5

Intranasal tat alters gene expression in the mouse brain.

Pulliam L, Sun B, Rempel H, Martinez PM, Hoekman JD, Rao RJ, Frey WH 2nd, Hanson LR. Pulliam L, et al. Among authors: hanson lr. J Neuroimmune Pharmacol. 2007 Mar;2(1):87-92. doi: 10.1007/s11481-006-9053-z. Epub 2007 Jan 9. J Neuroimmune Pharmacol. 2007. PMID: 18040830

6

Delivery of interferon-beta to the monkey nervous system following intranasal administration.

Thorne RG, Hanson LR, Ross TM, Tung D, Frey WH 2nd. Thorne RG, et al. Among authors: hanson lr. Neuroscience. 2008 Mar 27;152(3):785-97. doi: 10.1016/j.neuroscience.2008.01.013. Epub 2008 Jan 16. Neuroscience. 2008. PMID: 18304744

7

Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system.

Dhuria SV, Hanson LR, Frey WH 2nd. Dhuria SV, et al. J Pharmacol Exp Ther. 2009 Jan;328(1):312-20. doi: 10.1124/jpet.108.145565. Epub 2008 Oct 22. J Pharmacol Exp Ther. 2009. PMID: 18945930

8

Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy.

Francis GJ, Martinez JA, Liu WQ, Xu K, Ayer A, Fine J, Tuor UI, Glazner G, Hanson LR, Frey WH 2nd, Toth C. Francis GJ, et al. Brain. 2008 Dec;131(Pt 12):3311-34. doi: 10.1093/brain/awn288. Epub 2008 Nov 16. Brain. 2008. Retraction in: Brain. 2014 Jun;137(Pt 6):e283. doi: 10.1093/brain/awu127 PMID: 19015157 Retracted.

9

Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system.

Dhuria SV, Hanson LR, Frey WH 2nd. Dhuria SV, et al. J Pharm Sci. 2009 Jul;98(7):2501-15. doi: 10.1002/jps.21604. J Pharm Sci. 2009. PMID: 19025760

10

Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease.

Hanson LR, Frey WH 2nd. Hanson LR, et al. BMC Neurosci. 2008 Dec 10;9 Suppl 3(Suppl 3):S5. doi: 10.1186/1471-2202-9-S3-S5. BMC Neurosci. 2008. PMID: 19091002 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,592 results

Search Page

Filters